AMED

Amedisys, Inc. [AMED] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AMED Stock Summary

Top 10 Correlated ETFs

AMED


Top 10 Correlated Stocks

AMED


In the News

12:41 26 Feb 2024 AMED

AMED vs. USPH: Which Stock Is the Better Value Option?

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH). But which of these two stocks offers value investors a better bang for their buck right now?

09:01 26 Feb 2024 AMED

Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

07:01 26 Feb 2024 AMED

Amedisys (AMED) Q4 Earnings Lag Estimates

Amedisys (AMED) came out with quarterly earnings of $0.94 per share, missing the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.16 per share a year ago.

11:06 26 Feb 2024 AMED

Amedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

12:47 26 Feb 2024 AMED

Amedisys (AMED) Up 2.6% Since Last Earnings Report: Can It Continue?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

10:08 26 Feb 2024 AMED

Amedisys, Inc.: Why Stock Is A Hold Pending Agency Review

Amedisys, Inc. is set to be acquired by UnitedHealth Group in a $3.29 billion merger agreement. Some US legislators have called for further scrutiny of the merger, citing concerns of increased market dominance and higher medical costs. UnitedHealth's subsidiary, Optum Group, has been expanding its service provision through acquisitions, including a recent deal with UK health-tech company EMIS Group.

09:02 26 Feb 2024 AMED

Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

07:33 26 Feb 2024 AMED

Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates

Amedisys (AMED) came out with quarterly earnings of $0.98 per share, missing the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.15 per share a year ago.

11:19 26 Feb 2024 AMED

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.

01:15 26 Feb 2024 AMED

Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip

Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.

AMED Financial details

Company Rating
Strong Buy
Market Cap
3.08B
Income
2.65M
Revenue
2.23B
Book val./share
31.88
Cash/share
2.39
Dividend
-
Dividend %
-
Employees
18.6K
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
1153.3
Forward P/E
21.03
PEG
-117.16
P/S
1.37
P/B
2.94
P/C
39.51
P/FCF
29.06
Quick Ratio
0.85
Current Ratio
1
Debt / Equity
0.47
LT Debt / Equity
0.39
-
-
EPS (TTM)
0.1
EPS next Y
4.49
EPS next Q
1.05
EPS this Y
-43.06%
EPS next Y
4390%
EPS next 5Y
4390%
EPS last 5Y
0.05%
Revenue last 5Y
5.98%
Revenue Q/Q
0.59%
EPS Q/Q
-132.52%
-
-
-
-
SMA20
-1.05%
SMA50
0.1%
SMA100
0.12%
Inst Own
67.69%
Inst Trans
0.75%
ROA
-
ROE
-
ROC
0.11%
Gross Margin
44%
Oper. Margin
8%
Profit Margin
-
Payout
569%
Shs Outstand
32.63M
Shs Float
31.91M
-
-
-
-
Target Price
153.28
52W Range
69.36-96.44
52W High
-1.65%
52W Low
+36.84%
RSI
53.52
Rel Volume
0.57
Avg Volume
302K
Volume
173.34K
Perf Week
0.87%
Perf Month
0.85%
Perf Quarter
0.71%
Perf Half Y
1.44%
-
-
-
-
Beta
0.865
-
-
Volatility
0.46%, 0.59%
Prev Close
-0.08%
Price
94.42
Change
0.92%

AMED Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
50.760.8463.6267.8368.37
Net income per share
3.643.955.646.43.65
Operating cash flow per share
6.826.288.875.794.1
Free cash flow per share
6.626.048.715.583.88
Cash per share
0.620.942.511.311.25
Book value per share
14.6919.9324.8528.5332.34
Tangible book value per share
3.32-2.54-6.02-10.14-8.67
Share holders equity per share
14.6919.9324.8528.5332.34
Interest debt per share
0.4510.69.7717.0117.23
Market cap
3.84B5.37B9.55B5.28B2.72B
Enterprise value
3.83B5.66B9.78B5.79B3.21B
P/E ratio
32.1842.352.0225.2722.9
Price to sales ratio
2.312.744.612.391.22
POCF ratio
17.1826.5633.0527.9720.38
PFCF ratio
17.727.6433.6729.0121.55
P/B Ratio
7.978.3811.85.672.58
PTB ratio
7.978.3811.85.672.58
EV to sales
2.32.894.722.611.45
Enterprise value over EBITDA
21.3123.5233.2617.5412.53
EV to operating cash flow
17.1328.0233.8330.6424.11
EV to free cash flow
17.6429.1634.4731.7725.49
Earnings yield
0.030.020.020.040.04
Free cash flow yield
0.060.040.030.030.05
Debt to equity
0.020.510.380.590.51
Debt to assets
0.010.260.20.290.27
Net debt to EBITDA
-0.071.230.771.521.94
Current ratio
1.011.070.790.951.09
Interest coverage
21.0512.2319.8626.458.13
Income quality
1.861.581.560.91.13
Dividend Yield
0.040.590.370.750
Payout ratio
1.2125.1319.418.980
Sales general and administrative to revenue
0.30.310.320.320.34
Research and developement to revenue
00000
Intangibles to total assets
0.520.570.640.70.7
Capex to operating cash flow
-0.03-0.04-0.02-0.04-0.05
Capex to revenue
00000
Capex to depreciation
-0.49-0.15-0.08-0.09-0.1
Stock based compensation to revenue
0.010.010.010.010.01
Graham number
34.6842.0656.1664.1251.52
ROIC
0.240.130.160.120.08
Return on tangible assets
0.350.240.330.380.2
Graham Net
-2.1-11.68-14.66-19.15-18.27
Working capital
1.64M23.61M-94.35M-17.6M33.43M
Tangible asset value
109.02M-81.74M-196.13M-330.96M-281.99M
Net current asset value
-10.37M-270.68M-394.47M-523.96M-480.71M
Invested capital
0.020.510.380.590.51
Average receivables
195.08M213.28M246.37M265.05M285.87M
Average payables
26.96M29.9M36.97M40.45M40.98M
Average inventory
7.45M41M43.1M12.6M19.33M
Days sales outstanding
41.4944.3444.9645.3348.73
Days payables outstanding
10.499.9213.1411.3112.66
Days of inventory on hand
2.7823.623.623.977.3
Receivables turnover
8.88.238.128.057.49
Payables turnover
34.836.827.7832.2728.82
Inventory turnover
131.1915.45100.7591.8349.98
ROE
0.250.20.230.220.11
Capex per share
-0.2-0.25-0.16-0.21-0.22

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
17.1817.2917.0916.9717.05
Net income per share
0.790.980.78-2.460.8
Operating cash flow per share
-0.421.260.81.86-0.3
Free cash flow per share
-0.481.20.751.62-0.34
Cash per share
0.551.251.522.932.39
Book value per share
31.2732.3533.1430.931.88
Tangible book value per share
-9.84-8.67-6.49-8.86-7.81
Share holders equity per share
31.2732.3533.1430.931.88
Interest debt per share
17.4516.7215.1415.1715.27
Market cap
3.14B2.72B2.39B2.98B3.05B
Enterprise value
3.69B3.21B2.83B3.37B3.46B
P/E ratio
30.6521.4123.71-9.2829.34
Price to sales ratio
5.634.834.35.395.48
POCF ratio
-230.6666.4392.2449.03-309.57
PFCF ratio
-203.1669.998.1456.31-275.98
P/B Ratio
3.12.582.222.962.93
PTB ratio
3.12.582.222.962.93
EV to sales
6.615.725.096.16.22
Enterprise value over EBITDA
60.8750.5350.0651.2152.84
EV to operating cash flow
-270.5878.6109.0355.47-351.44
EV to free cash flow
-238.3282.7116.0163.7-313.3
Earnings yield
0.010.010.01-0.030.01
Free cash flow yield
00.010.010.020
Debt to equity
0.550.510.450.480.47
Debt to assets
0.280.270.250.250.24
Net debt to EBITDA
8.987.827.715.956.29
Current ratio
1.061.091.150.921
Interest coverage
7.8485.645.045.26
Income quality
-0.541.31.04-0.75-0.38
Dividend Yield
0000.010
Payout ratio
000-0.190
Sales general and administrative to revenue
0.340.340.350.390.35
Research and developement to revenue
00000
Intangibles to total assets
0.70.70.690.680.67
Capex to operating cash flow
0.14-0.05-0.06-0.130.12
Capex to revenue
000-0.010
Capex to depreciation
-0.1-0.12-0.11-0.54-0.08
Stock based compensation to revenue
0.0100.010.020.01
Graham number
23.5726.6524.0541.3923.89
ROIC
0.020.020.020.030.02
Return on tangible assets
0.040.050.04-0.130.04
Graham Net
-20.09-18.27-16.11-18.49-18.33
Working capital
21.58M33.43M52.51M-35.86M-892K
Tangible asset value
-319.52M-281.99M-211.26M-288.67M-254.8M
Net current asset value
-523.74M-480.71M-408.05M-495.1M-466.67M
Invested capital
0.550.510.450.480.47
Average receivables
303.94M299.63M295.45M286.45M299.18M
Average payables
44.52M44.63M41.88M39.29M36.56M
Average inventory
33.96M27.87M31.82M33.99M33M
Days sales outstanding
48.7947.5247.5845.3751.71
Days payables outstanding
12.7212.4111.4311.679.98
Days of inventory on hand
8.527.1610.988.9410.52
Receivables turnover
1.841.891.891.981.74
Payables turnover
7.087.257.877.719.02
Inventory turnover
10.5612.588.210.068.55
ROE
0.030.030.02-0.080.02
Capex per share
-0.06-0.06-0.05-0.24-0.04

AMED Frequently Asked Questions

What is Amedisys, Inc. stock symbol ?

Amedisys, Inc. is a US stock , located in Baton rouge of La and trading under the symbol AMED

Is Amedisys, Inc. buy or a sell ?

13 stock analysts have 13 predictions with a medium analyst target price of $159.91. The lowest prediction is $85 and the highest is $230

What is AMED stock prediction ?

What is Amedisys, Inc. stock quote today ?

Amedisys, Inc. stock price is $94.42 today.

Is Amedisys, Inc. stock public?

Yes, Amedisys, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap